ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma
, restricted tumor growth in an immunocompetent mouse model. Our findings provide preclinical support for combined antisense therapy and ICB for PDAC patients, highlighting the critical role of PKM2 in the TME and its potential as a therapeutic target.
Authors
- Lijie Han (ORCID: https://orcid.org/0000-0001-5919-3773)
- Marvin H. Caruthers (ORCID: https://orcid.org/0000-0002-4931-468X)
- Dillon M. Voss (ORCID: https://orcid.org/0000-0001-7481-9455)
- Mathias Danielsen
- Ting Wang (ORCID: https://orcid.org/0000-0001-7944-0700)
- Adrian R. Krainer (ORCID: https://orcid.org/0000-0001-9024-9501)
- Ondřej Kostov (ORCID: https://orcid.org/0000-0002-0194-1852)
- Hao Chen
- Lina Gan
- Jia Liu
- Balázs Schäfer
Institutions
- Shanghai Jiao Tong University (CN)
- University of Colorado Boulder (US)
- Cold Spring Harbor Laboratory (US)
- Ruijin Hospital (CN)
- Stony Brook School (US)
- Stony Brook University (US)
Publication Details
- Journal
- Cell Discovery
- Published
- 2026-04-21
- DOI
- https://doi.org/10.1038/s41421-026-00882-9
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00